🇺🇸 FDA
Patent

US 11426467

Dosage regimes for the administration of an anti-CD25 ADC

granted A61KA61K2039/545A61K31/5517

Quick answer

US patent 11426467 (Dosage regimes for the administration of an anti-CD25 ADC) held by ADC THERAPEUTICS SA expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ADC THERAPEUTICS SA
Grant date
Tue Aug 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/545, A61K31/5517, A61K39/3955, A61K45/06